Mycophenolate mofetil (MMF)-containing products: Risk of pregnancy loss and congenital malformations – Extension of the post‑treatment contraception period from 6 weeks to 6 months for women of childbearing potential - SAHPRA

Covid-19 | Subscribe

Mycophenolate mofetil (MMF)-containing products: Risk of pregnancy loss and congenital malformations – Extension of the post‑treatment contraception period from 6 weeks to 6 months for women of childbearing potential

Home > Mycophenolate mofetil (MMF)-containing products: Risk of pregnancy loss and congenital malformations – Extension of the post‑treatment contraception period from 6 weeks to 6 months for women of childbearing potential

22 Oct Mycophenolate mofetil (MMF)-containing products: Risk of pregnancy loss and congenital malformations – Extension of the post‑treatment contraception period from 6 weeks to 6 months for women of childbearing potential

Posted at 10:38h in by

CellCept, Mycocept, Mycophenolate Teva and Mycokem are medicines that contain the active ingredient mycophenolate mofetil (MMF). Roche Products (Pty) Ltd, Sandoz South Africa (Pty) Ltd, Teva Pharmaceuticals (Pty) Ltd, and Ascend Laboratories (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the following:

Download latest version
Document Number: DHCPL
Version: 1
Date Updated: 22/10/2026
File Type: www
Category: Communication To Health Care Professionals
Unit: Pharmacovigilance